Pancreatic cancer, “Aifa revises the no to olaparib”: appeal of oncologists and patients

(Adnkronos) – Michele Reni (San Raffaele oncologist), defining whether a drug has value and offers benefits is not easy. Better to start a discussion with experts who deal with it because the value of a drug must be contextualised. Mario Sala (patient), I hope they mend their ways. Thanks to olaparib I have a good quality of life. Two pills instead of chemo I think there’s a big difference.